AnaptysBio (NASDAQ:ANAB) Given Neutral Rating at HC Wainwright

AnaptysBio (NASDAQ:ANAB)‘s stock had its “neutral” rating reaffirmed by research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $19.00 price target on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 14.05% from the stock’s previous close.

ANAB has been the subject of several other research reports. Truist Financial decreased their target price on AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th. UBS Group raised their price objective on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Wells Fargo & Company dropped their target price on shares of AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a report on Thursday, December 12th. BTIG Research lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. Finally, JPMorgan Chase & Co. cut their price objective on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, AnaptysBio presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.45.

AnaptysBio Trading Down 7.1 %

AnaptysBio stock opened at $16.66 on Tuesday. The company’s 50-day moving average price is $17.38 and its two-hundred day moving average price is $27.01. The stock has a market cap of $506.96 million and a price-to-earnings ratio of -2.74. AnaptysBio has a 52 week low of $12.51 and a 52 week high of $41.31.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $7.92 million. Research analysts expect that AnaptysBio will post -6.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In other AnaptysBio news, Director Ecor1 Capital, Llc bought 6,646 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were bought at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the acquisition, the director now directly owns 7,880,094 shares of the company’s stock, valued at approximately $102,047,217.30. This trade represents a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 33.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC boosted its stake in shares of AnaptysBio by 15.3% during the 3rd quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock valued at $110,857,000 after buying an additional 438,557 shares during the period. Jennison Associates LLC acquired a new stake in AnaptysBio during the third quarter valued at $8,874,000. Victory Capital Management Inc. grew its stake in AnaptysBio by 677.9% in the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock valued at $7,948,000 after purchasing an additional 206,750 shares in the last quarter. Assenagon Asset Management S.A. increased its position in AnaptysBio by 55.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after purchasing an additional 168,813 shares during the last quarter. Finally, Walleye Capital LLC purchased a new stake in shares of AnaptysBio during the 3rd quarter worth about $5,494,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.